Select Page

Teva closed its acquisition of Allergan Generics for $40.5 billion after obtaining regulatory approval from the US Federal Trade Commission a week ago. Anda distributes generic, brand, specialty and over-the-counter pharmaceutical products from more than 300 manufacturers to retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices across the United States. The company was established in 1992. For the full year 2016, Anda is expected to generate more than $1 billion in third-party net revenue. As part of the deal, Teva will acquire three distribution centers in Olive Branch, Miss.; Weston, Fla.; and Groveport, Ohio, with a total of over 650 employees. “Anda is a natural fit into our business in general and our extensive supply chain network in particular,” said Siggi Olafsson, president & CEO of Teva’s Global Generic Medicines. “We believe Anda is truly a unique company which further enhances the offerings that Teva can provide. This strategic move enables us and our customers to improve capabilities and flexibility given the changes the pharmaceutical industry is currently undergoing, in order to provide access to more patients throughout the country. Additionally, both Teva and Anda’s customers will benefit from our ability as the largest producer of medicines in the world to leverage our size and scale.” “Joining Teva opens a new world of possibilities for Anda, especially as the appropriate utilization of generic medicines remains the most effective means by which to ensure broad patient access,” said Charles D. Phillips, president & CEO of Anda. “Anda will continue to operate as a stand-alone business and report directly to me. The addition of Anda and their ability to service over half of their 60,000 customers within 24 hours, combined with our existing offerings, will allow us to provide even better service to our customers,” Olafsson added. “The sale of Anda to Teva Pharmaceuticals is a strategic transaction that benefits Allergan and the employees and customers of the Anda business,” said Brent Saunders, CEO and president of Allergan. “For Allergan, this divestiture continues our evolution as a focused branded Growth Pharma leader, powered by growing leadership positions across our seven therapeutic areas, developing and bringing to market innovative therapies from our industry leading pipeline, simplified operating structure and adding new development programs through our Open Science R&D model.” The deal is subject to antitrust clearance and other customary conditions, and is expected to close in the second half of 2016. Teva leverages its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, the company has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. The company integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2015 amounted to $19.7 billion.]]>